β-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats

Clin Sci (Lond). 2015 Sep;129(6):505-13. doi: 10.1042/CS20150077. Epub 2015 May 8.

Abstract

We have previously shown that individual β-amino acid substitution in angiotensin (Ang) II reduced Ang II type 1 receptor (AT1R) but not Ang II type 2 receptor (AT2R)-binding and that the heptapeptide Ang III exhibited greater AT2R:AT1R selectivity than Ang II. Therefore, we hypothesized that β-amino-acid-substituted Ang III peptide analogues would yield highly selective AT2R ligands, which we have tested in binding and functional vascular assays. In competition binding experiments using either AT1R- or AT2R-transfected human embryonic kidney (HEK)-293 cells, novel β-substituted Ang III analogues lacked appreciable AT1R affinity, whereas most compounds could fully displace (125)I-Sar(1)Ile(8) Ang II from AT2R. The rank order of affinity at AT2R was CGP42112 > Ang III > β-Pro(7) Ang III=Ang II > β-Tyr(4) Ang III ≥ PD123319 >> β-Phe(8) Ang III >> β Arg(2) Ang III=β-Val(3) Ang III >> β-Ile(5) Ang III. The novel analogue β-Pro(7) Ang III was the most selective AT2R ligand tested, which was >20,000-fold more selective for AT2R than AT1R. IC50 values at AT2R from binding studies correlated with maximum vasorelaxation in mouse aortic rings. Given that β-Pro(7) Ang III was an AT2R agonist, we compared β-Pro(7) Ang III and native Ang III for their ability to reduce blood pressure in separate groups of conscious spontaneously hypertensive rats. Whereas Ang III alone increased mean arterial pressure (MAP), β-Pro(7) Ang III had no effect. During low-level AT1R blockade, both Ang III and β-Pro(7) Ang III, but not Ang II, lowered MAP (by ∼30 mmHg) at equimolar infusions (150 pmol/kg/min for 4 h) and these depressor effects were abolished by the co-administration of the AT2R antagonist PD123319. Thus, β-Pro(7) Ang III has remarkable AT2R selectivity determined in binding and functional studies and will be a valuable research tool for insight into AT2R function and for future drug development.

Keywords: angiotensin II type 2 (AT2) receptor; angiotensin III; blood pressure; vasorelaxation; β-amino acid substitutions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Analysis of Variance
  • Angiotensin II Type 2 Receptor Blockers / pharmacology*
  • Angiotensin III / analogs & derivatives*
  • Angiotensin III / blood
  • Angiotensin III / pharmacology
  • Animals
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / physiopathology
  • Benzimidazoles / metabolism
  • Binding, Competitive
  • Biphenyl Compounds
  • Drug Stability
  • HEK293 Cells
  • Humans
  • Hypertension / drug therapy*
  • Imidazoles / pharmacology*
  • In Vitro Techniques
  • Inhibitory Concentration 50
  • Isometric Contraction / drug effects
  • Male
  • Mice
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiopathology
  • Pyridines / pharmacology*
  • Rats
  • Receptors, Angiotensin / chemistry
  • Receptors, Angiotensin / metabolism
  • Tetrazoles / metabolism
  • Vasoconstrictor Agents / pharmacology*
  • Vasodilation / drug effects

Substances

  • Angiotensin II Type 2 Receptor Blockers
  • Benzimidazoles
  • Biphenyl Compounds
  • Imidazoles
  • Pyridines
  • Receptors, Angiotensin
  • Tetrazoles
  • Vasoconstrictor Agents
  • angiotensin III, beta-Pro(7)-
  • Angiotensin III
  • PD 123319
  • candesartan